打头阵！南京气势澎湃开新局。 1月4日，新年第一个工作日，南京召开全市科技创新和产业创新深度融合发展大会。会上围绕产业引 领、创新高地、生态优化三个方面进行了政策、成果、技术需求发布，一揽子项目同步签约、揭牌—— 紧盯前沿，南京发布深入推进"人工智能+"行动实施方案和打造"6G之城"行动计划；务实攻坚，38项关 键技术攻关需求等待"揭榜挂帅"；求贤若渴，人才政策2.0及"南京人才求贤帖"亮相，每年汇聚不少于 30万名青年人才；真金白银，"紫金山国际科创基金街区"建设方案发布并揭牌，将进一步集聚科创金融 资源，搭建多元化金融服务平台……在这片专为创新营造的政策"热带雨林"里，产业发展的势头日渐强 劲。 "在推动科技创新和产业创新融合上打头阵"是习近平总书记赋予江苏的重大使命。面向"十五五"开局之 年，南京瞄准"建设具有全球影响力的产业科技创新中心主承载区"，正加快推进科技创新和产业创新深 度融合，奋力推动产业强市建设，切实扛起走在前、做示范、挑大梁的省会担当。 攻坚产业，成体系锻造硬核实力 大会现场，江苏省工信厅与南京市政府签订战略合作协议，通过省市协同联动，整合优质资源、凝聚发 展合力，为南京重点产业集群升级 ...

"达嘉维康再生医学研究院是达嘉维康在生命健康领域的重要战略布局，作为中心共建单位，将全程投入技术、人才、资 金，加速推动前沿疗法从实验室走向临床实践"。湖南达嘉维康医药产业股份有限公司（以下简称"达嘉维康"）董事长王毅清 表示，已经为中心工作开展建设了符合GMP标准的细胞库与实验室、国际标准样本存储库，打造从细胞采集、存储、制备到应 用的完整产业链，不断提升产品的安全性、有效性，让老百姓面对细胞治疗产品敢用、想用、用得上。 （编辑 郭之宸） 该中心由湖南大学牵头，联合湖南省肿瘤医院、湘雅医院器官损伤衰老与再生医学湖南省重点实验室、湘潭市中心医院、 长沙市第三医院、长沙市口腔医院、长沙市妇幼保健院、湖南达嘉维康再生医学研究院共同组建，旨在整合"产学研医"协同创 新优势，聚焦重大疾病诊断治疗、组织器官损伤修复等领域，以临床带动科研，以专业赋能产业，开辟一条科研与产业融合发 展的新路径，引领再生医学产业高质量发展。 细胞治疗等再生医学技术，是利用干细胞和免疫细胞的特性，激活和修复组织器官，被誉为是"第三次医学革命"。当前， 全球细胞治疗市场规模已突破4000亿美元。湖南省正着力打造千亿元级干细胞与再生医学产业链，长 ...

Group 1 - The core viewpoint of the news is that Liaoning Fangda Group has shown resilience and growth across its various sectors, ranking 126th in the 2025 China Top 500 Enterprises and 40th in the Top 100 Leading Enterprises in Strategic Emerging Industries [1] - The company focuses on five major sectors: carbon products, steel, pharmaceuticals, commerce, and aviation, aiming to develop new productive forces and achieve stable growth [1] - In the first eight months of 2025, the company emphasized its commitment to national strategies and innovation, adapting to market pressures from raw material price fluctuations and steel demand [1] Group 2 - Fangda Steel Group achieved a sales revenue of 46.317 billion yuan and a profit of 1.699 billion yuan in the first half of the year, with its subsidiaries ranking high in profitability within the industry [2] - The pharmaceutical sector, particularly Northeast Pharmaceutical, is advancing in cell therapy for various cancers, with over ten products in development and a strong research pipeline [2] - The commercial sector, represented by Zhongxing Commercial, reported a 25.08% increase in net profit year-on-year, while Tianjin Yishang's revenue exceeded 7.1 billion yuan with a 63% profit increase [3] Group 3 - HNA Group, part of the aviation sector, launched the "HNA PLUS Membership Card" to enhance service offerings and received multiple awards for its airlines, achieving record passenger numbers during the summer travel season [3] - The company is committed to aligning its development with national strategies and regulations, focusing on technological innovation to contribute to high-quality economic growth in China [4]

Core Insights - The rise of precision medicine in the Asia-Pacific region is not only a transformation in medical technology but also a core force reshaping the regional economic landscape [1] - A new study by L.E.K. Consulting indicates that precision medicine is expected to generate approximately 14.5 trillion RMB (2,000 billion USD) in direct economic investment in China's pharmaceutical value chain over the next decade [1] - The study also forecasts the creation of up to 142,000 high-skilled jobs in the pharmaceutical value chain and additional employment opportunities in diagnostics and healthcare systems [1][2] Economic Impact - Precision medicine is projected to create an indirect economic benefit of up to 8.7 trillion RMB (1,200 billion USD) through its multiplier effect on related industries [1] - The expected increase in patient lifespan is estimated to be 9.2 million years, alongside a reduction in medical expenses by 216 billion RMB (30 billion USD), alleviating pressure on China's healthcare resources [1] Investment Focus - Investments will cover research and development, production, and commercialization, with R&D and commercialization expected to receive the largest funding [2] - Targeted antibody drugs will remain a primary focus for funding, while cell therapy, gene therapy, and companion diagnostics are anticipated to be rapidly growing sectors [2] Healthcare Transformation - Precision medicine aims to optimize diagnostic and treatment outcomes, reduce waste in medical resources, and clarify the causes of rare diseases [4] - The long-term investment in precision medicine is expected to enhance healthcare infrastructure and create high-quality job opportunities, stimulating broader economic activity [4] Regulatory Environment - The Chinese government plays a crucial role in optimizing drug approval processes and regulatory frameworks, which is essential for the success of precision medicine [5][9] - Recent reforms have aimed to accelerate the approval of urgently needed cell and gene therapies, reflecting a commitment to enhancing regulatory efficiency [9] Data and Technology - The rise of AI technology presents new opportunities for the intelligent transformation of the healthcare industry and the development of precision medicine [10] - However, there are challenges related to data sharing and privacy, which need to be addressed to fully leverage clinical and genetic data for research and patient care [10][11] Future Outlook - The ongoing development of a multi-tiered healthcare security system in China is expected to better meet diverse patient needs and enhance overall patient benefits [6][7] - The precision medicine sector is seen as a significant growth area, with the potential to reshape the economy and improve health outcomes for millions [12]

Group 1 - Precision medicine is reshaping the economic landscape in the Asia-Pacific region, with an estimated direct economic investment of approximately 1.45 trillion RMB (200 billion USD) in China's pharmaceutical value chain over the next decade [1] - The sector is expected to create up to 142,000 high-skilled jobs and generate an additional 870 billion RMB (120 billion USD) in indirect economic benefits [1][2] - Targeted antibody drugs, cell therapy, gene therapy, and companion diagnostics are identified as key areas for investment and growth [2][4] Group 2 - The investment in precision medicine will enhance healthcare accessibility and reduce medical expenses by approximately 216 billion RMB (30 billion USD), alleviating pressure on China's medical resources [1][3] - The development of precision medicine is a long-term process that will not only benefit patients but also upgrade medical infrastructure and create high-quality employment opportunities [3][5] - The Chinese government plays a crucial role in optimizing drug approval processes and enhancing the regulatory framework to support innovative therapies [6][8] Group 3 - The rise of AI technology is providing new opportunities for the intelligent transformation of the healthcare industry, which is essential for the development of precision medicine [7][8] - There is a need for improved data sharing and connectivity among medical institutions to facilitate the effective use of clinical and genetic data [7][8] - The global emphasis on data security and privacy protection necessitates compliance with regional policies and regulations, especially concerning cross-border data flow [8][9]

Core Viewpoint - JD.com is actively recruiting a head for its Cell Research Institute with a salary of one million, indicating its strategic focus on cell therapy as a significant breakthrough in the high-end medical services sector, with "cell storage" as a core business entry point [1][3][5]. Group 1 - The recruitment of a head for the Cell Research Institute has sparked discussions within the cell and gene therapy (CGT) industry [3]. - The job requirements highlight the need for experience in the commercialization of cell therapy products and practical experience with at least one CGT product's IND progress, suggesting JD.com's serious commitment to this field [5]. - JD.com has shown a strategic determination to deeply engage in the cell therapy sector, leveraging its strong financial resources, large user base, and e-commerce platform traffic to potentially disrupt traditional industry competition [8].